Composition, form of production and packaging
The tablets covered with a film membrane from light yellow to yellow-orange color, round, biconcave, slightly rough; two layers are visible on the cross section: the core is white or white with a slightly yellowish tinge and a sheath from light yellow to yellow-orange.
Inosine 200 mg
[PRING] potato starch 54.1 mg, methylcellulose 3.2 mg, sucrose 10 mg, stearic acid 2.7 mg.
Sheath composition: opedrail II yellow (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350 (polyethylene glycol 3350), iron (III) oxide, lacquer aluminum based on quinoline yellow) - 8 mg.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
25 pcs. - packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
Inosine belongs to the group of drugs that regulate metabolic processes. The drug is a precursor of the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate.
Has antihypoxic, metabolic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate.
Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the shock volume of blood.
Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane of the gastrointestinal tract.
It is well absorbed in the gastrointestinal tract. Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.
Assign adults in the complex therapy of coronary heart disease, after a heart attack, myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.
Assign with hepatitis, cirrhosis, fatty liver, caused by alcohol or drugs and urocoppororphy.
Assign adults inside, before eating.
The daily intake for oral administration is 0.6-2.4 g. In the first days of treatment the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day.
The duration of the course is from 4 weeks to 1.5-3 months.
With urocoppororphy, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.
Allergic reactions are possible in the form of hives, itchy skin, skin hyperemia (drug withdrawal is required). Rarely with the treatment of the drug raises the concentration of uric acid in the blood and exacerbation of gout (with prolonged use).
Hypersensitivity to the drug, gout, hyperuricemia. Fructose intolerance and glucose / galactose absorption disorder or sugar / isomaltase deficiency.
Carefully. Renal insufficiency, diabetes mellitus.
PREGNANCY AND LACTATION
The safety of the drug Riboxin during pregnancy and lactation is not established. Riboxin is contraindicated during pregnancy. For the duration of treatment with Riboxin, breastfeeding should be discontinued.
APPLICATION FOR FUNCTIONS OF THE LIVER
With caution: kidney failure.
During the treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.
Information for patients with diabetes: 1 tablet of the drug corresponds to 0.00641 units of bread.
Does not affect the ability to drive vehicles and manage mechanisms that require increased concentration.
Immunosuppressants (azathioprine, antilympholine, cyclosporine, thymodepressin, etc.) with simultaneous use reduce the effectiveness of Riboxin.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
In a dry, protected from light place at a temperature of no higher than 25 В° C. Keep out of the reach of children.
Shelf life. 3 years. Do not use after the expiry date printed on the package.